Compile Data Set for Download or QSAR
Report error Found 328 Enz. Inhib. hit(s) with all data for entry = 10649
TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM454840(US10730874, Compound I-1 | US11352356, Compound I-...)
Affinity DataEC50:  55nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM454849(US10730874, Compound I-2 | US10730874, Compound I-...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM454918(US10730874, Compound I-3 | US10730874, Compound TA...)
Affinity DataEC50:  55nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM454941(US10730874, Compound I-4 | US11352356, Compound I-...)
Affinity DataEC50:  5.5nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM454966(US10730874, Compound I-5 | US11352356, Compound I-...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM557344(US11352356, Compound I-6)
Affinity DataEC50:  5.5nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM454983(US10730874, Compound I-7 | US11352356, Compound I-...)
Affinity DataEC50:  5.5nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM454984(US10730874, Compound I-8 | US11352356, Compound I-...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM454985(US10730874, Compound I-9 | US11352356, Compound I-...)
Affinity DataEC50:  55nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM454986(US10730874, Compound I-10 | US11352356, Compound I...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM557349(US11352356, Compound I-11)
Affinity DataEC50:  5.5nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM557350(US11352356, Compound I-12)
Affinity DataEC50:  55nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM454989(US10730874, Compound I-13 | US11352356, Compound I...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM454990(US10730874, Compound I-14 | US11352356, Compound I...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM454991(US10730874, Compound I-15 | US11352356, Compound I...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM454992(US10730874, Compound I-16 | US11352356, Compound I...)
Affinity DataEC50:  5.5nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM454993(US10730874, Compound I-17 | US11352356, Compound I...)
Affinity DataEC50:  5.5nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM454994(US10730874, Compound I-18 | US11352356, Compound I...)
Affinity DataEC50:  5.5nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM454995(US10730874, Compound I-19 | US11352356, Compound I...)
Affinity DataEC50:  5.5nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM454996(US10730874, Compound I-20 | US11352356, Compound I...)
Affinity DataEC50:  5.5nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM557359(US11352356, Compound I-21)
Affinity DataEC50:  5.5nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM454998(US10730874, Compound I-22 | US11352356, Compound I...)
Affinity DataEC50:  1.05E+3nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM454999(US10730874, Compound I-23 | US11352356, Compound I...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM455000(US10730874, Compound I-24 | US11352356, Compound I...)
Affinity DataEC50:  5.5nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM455001(US10730874, Compound I-25 | US11352356, Compound I...)
Affinity DataEC50:  5.5nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM455002(US10730874, Compound I-26 | US11352356, Compound I...)
Affinity DataEC50:  5.5nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM455003(US10730874, Compound I-27 | US11352356, Compound I...)
Affinity DataEC50:  5.5nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM455004(BDBM557366 | US10730874, Compound I-28)
Affinity DataEC50:  5.5nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM455005(US10730874, Compound I-29 | US11352356, Compound I...)
Affinity DataEC50:  55nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM455006(US10730874, Compound I-30 | US11352356, Compound I...)
Affinity DataEC50:  5.5nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM455007(US10730874, Compound I-31 | US10730874, Compound I...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM455008(US10730874, Compound I-32 | US11352356, Compound I...)
Affinity DataEC50:  55nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM455009(US10730874, Compound I-33 | US11352356, Compound I...)
Affinity DataEC50:  55nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM455010(US10730874, Compound I-34 | US11352356, Compound I...)
Affinity DataEC50:  55nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM557373(US11352356, Compound I-35)
Affinity DataEC50:  1.05E+3nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM557374(US11352356, Compound I-36)
Affinity DataEC50:  55nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM557375(US11352356, Compound I-37)
Affinity DataEC50:  55nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM455014(US10730874, Compound I-38 | US11352356, Compound I...)
Affinity DataEC50:  5.5nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM455015(US10730874, Compound I-39 | US11352356, Compound I...)
Affinity DataEC50:  5.5nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM455016(US10730874, Compound I-40 | US11352356, Compound I...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM557379(US11352356, Compound I-41)
Affinity DataEC50:  55nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM557380(US11352356, Compound I-42)
Affinity DataEC50:  55nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM455019(US10730874, Compound I-43 | US11352356, Compound I...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM455020(US10730874, Compound I-44 | US11352356, Compound I...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM455021(US10730874, Compound I-45 | US11352356, Compound I...)
Affinity DataEC50:  5.5nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM455022(US10730874, Compound I-46 | US11352356, Compound I...)
Affinity DataEC50:  55nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM455023(US10730874, Compound I-47 | US11352356, Compound I...)
Affinity DataEC50:  5.5nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM557386(US11352356, Compound I-48)
Affinity DataEC50:  1.05E+3nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM455025(US10730874, Compound I-49 | US11352356, Compound I...)
Affinity DataEC50:  55nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM557388(US11352356, Compound I-50)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
Go to US Patent

Displayed 1 to 50 (of 328 total ) | Next | Last >>
Jump to: